0001213900-23-062982.txt : 20230803 0001213900-23-062982.hdr.sgml : 20230803 20230803160559 ACCESSION NUMBER: 0001213900-23-062982 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sensus Healthcare, Inc. CENTRAL INDEX KEY: 0001494891 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 271647271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37714 FILM NUMBER: 231139866 BUSINESS ADDRESS: STREET 1: 851 BROKEN SOUND PARKWAY NW STREET 2: SUITE 215 CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 561-922-5808 MAIL ADDRESS: STREET 1: 851 BROKEN SOUND PARKWAY NW STREET 2: SUITE 215 CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: Sensus Healthcare, LLC DATE OF NAME CHANGE: 20100622 8-K 1 ea182698-8k_sensus.htm CURRENT REPORT
0001494891 false 0001494891 2023-08-03 2023-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2023

 

SENSUS HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-37714

  

27-1647271

(State of Incorporation)   (Commission File Number)   (IRS Employer
Identification No.)

 

851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida

  

33487

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (561) 922-5808

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   SRTS   Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

SENSUS HEALTHCARE, INC.

 

FORM 8-K

CURRENT REPORT

 

Item 2.02Results of Operation and Financial Condition

 

On August 3, 2023, Sensus Healthcare, Inc. announced via press release its financial results for the second quarter of 2023. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

The press release makes reference to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release.

 

The information furnished under Item 2.02, including in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits

 

99.1   Press Release, dated August 3, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SENSUS HEALTHCARE, INC.
   
Date: August 3, 2023 By: /s/ Javier Rampolla
    Javier Rampolla
    Chief Financial Officer

 

2

 

 

EXHIBIT INDEX

 

Exhibit
Number		   Description
99.1   Press Release, dated August 3, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 

3

 

 EX-99.1 2 ea182698ex99-1_sensus.htm PRESS RELEASE, DATED AUGUST 3, 2023

Exhibit 99.1

 

 

Sensus Healthcare Reports Second Quarter 2023 Financial Results

 

●Revenues increased 33% and system shipments increased 30%, both compared with the first quarter of 2023
   
●Achieved a milestone with the installation of 700 systems for a total of 708
   
●Expects to ship at least 60 SRT units during 2023 and to return to profitability in the second half of the year

 

Conference call begins at 4:30 p.m. Eastern time today

 

BOCA RATON, Fla. (August 3, 2023) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2023.

 

Highlights from the second quarter of 2023 and recent weeks include the following:

 

●Achieved revenues of $4.5 million, an increase of 33% from $3.4 million for the first quarter of 2023 and a decrease from $12.1 million in the prior-year quarter reflecting lower SRT unit sales
   
●Shipped 13 SRT systems including four outside the U.S. and six SRT-100 Vision™ systems, an increase from 10 systems shipped during the first quarter of 2023 and a decrease from 33 systems shipped in the prior-year quarter
   
●Surpassed 700 total systems, with 708 sold worldwide.
   
●Narrowed the net loss to $0.4 million, or $0.02 per share, from a net loss of $1.9 million, or $0.12 per share, for the first quarter of 2023 and versus net income of $3.5 million, or $0.21 per diluted share, for the prior-year quarter
   
●Ended the quarter with $20.1 million in cash and cash equivalents, and no debt
   
●Sold the first SRT System in Ireland, to Dublin’s Beacon Hospital
   
●Engaged MIS Healthcare to distribute SRT systems in the United Kingdom and Ireland
   
●Anticipates profitability for the second half of the year based on a growing number of prospects

 

Management Commentary

 

“Many of our customers depend on elective aesthetic procedures as a meaningful source of practice revenue and profit, and we are hearing encouraging feedback that patient volumes and procedure mix are improving. Our second quarter financial results reflect that dynamic and strengthened considerably compared with the first quarter,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We expect to return to profitability in the second half of the year as these trends continue. In preparation, we continued to build inventory and prepay for components.

 

“International expansion is an important strategic goal and we were delighted to enter into a new partnership with MIS Healthcare to distribute SRT systems in the United Kingdom and British Isles. Prior to that engagement our internal sales staff had been working for several months with Beacon Hospital in Dublin, and we were delighted to have installed an SRT unit there during recent weeks. We believe Ireland holds excellent promise for SRT, with 600 people diagnosed with non-melanoma skin cancer each day. We also sold an SRT-100 System to a hospital in Guatemala as we advance our efforts in Latin America.

 

 

 

 

“Our plan is to enter three to four new territories over the coming years, and we are advancing this goal with sales to Southeast Asia and Latin America, in addition to the UK and Ireland. We are regaining momentum in China now that pandemic lockdowns have been lifted and shipped two SRT systems there during the second quarter, for a total of five shipments to Asia so far this year.

 

“Sentinel IT is our HIPAA-compliant software that stores patient data for multiple clinical purposes and will include artificial intelligence to allow customers to better manage their practices and data. Sentinel IT is expected to play a key role in our growth, and during the quarter we launched our Sentinel/Sensus Cloud capabilities at the American Academy of Dermatology Annual Meeting. We look forward to showcasing Sentinel IT and our SRT products at local dermatology trade shows, as well as at the American Society for Radiation Oncology beginning October 1st. Although the hospital market has a longer sales cycle, radiation oncology is a highly attractive opportunity as their interest expands to skin cancer.”

 

Mr. Sardano concluded, “With an estimated one in five Americans, or 70 million people expected to develop skin cancer during their lifetime, SRT is the No. 1 choice for the non-invasive treatment of non-melanoma skin cancer. SRT treatments surpassed 480,000 in the last two years alone and the ROI for our premium SRT system under our fair market value leasing program continues to be compelling, with breakeven at only 2 to 2.5 patients per month. Surveys of Medicare show that SRT has experienced a 27% treatment growth rate year over year for the past six years. If this growth utilization rate continues at its current pace, SRT will soon become the treatment of choice for non-melanoma skin cancer. Accordingly, professional interest in SRT remains high, and we expect to meet our objectives of shipping at least 60 SRT systems during 2023 and returning to profitability in the second half of the year.”

 

Second Quarter Financial Results

 

Revenues for the second quarter of 2023 were $4.5 million, compared with $12.1 million for the second quarter of 2022. The decrease was primarily due to a lower number of SRT units sold as customers continued to defer purchases, as well as to lower sales to a large customer.

 

Cost of sales was $1.9 million for the second quarter of 2023, compared with $3.8 million for the prior-year quarter. The decrease was primarily due to lower sales in the second quarter of 2023.

 

Gross profit for the second quarter of 2023 was $2.6 million, or 57.9% of revenues, compared with $8.3 million, or 68.3% of revenues, for the second quarter of 2022. The decrease was primarily due to the lower number of units sold and higher costs charged by vendors in the 2023 quarter.

 

Selling and marketing expense was $1.6 million for the second quarter of 2023, compared with $1.7 million for the prior-year quarter. The decrease was primarily attributable to a decrease in marketing initiatives and commissions, partially offset by an increase in headcount costs.

 

General and administrative expense was $1.3 million for the second quarter of 2023, compared with $1.1 million for the second quarter of 2022. The increase was primarily due to higher professional fees, offset by a reduction in insurance expense.

 

Research and development expense was $0.8 million for the second quarter of 2023, unchanged from the comparable 2022 period.

 

Other income of $0.2 million for the second quarter of 2023 was related to interest income.

 

Net loss for the second quarter of 2023 was $0.4 million, or $0.02 per share, compared with net income of $3.5 million, or $0.21 per diluted share, for the second quarter of 2022.

 

2

 

 

Adjusted EBITDA for the second quarter of 2023 was negative $1.0 million, compared with positive $4.7 million for the second quarter of 2022. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided.

 

Cash and cash equivalents were $20.1 million as of June 30, 2023, compared with $25.5 million as of December 31, 2022. The Company had no outstanding borrowings under its revolving line of credit as of June 30, 2023 or December 31, 2022. Prepaid and other current assets were $8.1 million as of June 30, 2023, compared with $6.9 million as of December 31, 2022. Inventories were $10.1 million as of June 30, 2023, compared with $3.5 million as of December 31, 2022, with the increase reflecting the Company’s expectations for higher unit sales during the second half of the year.

 

Six Month Financial Results

 

Revenues were $7.9 million for the first half of 2023, compared with $22.4 million for the first half of 2022, reflecting a lower number of units sold.

 

Cost of sales was $3.7 million for the first half of 2023, compared with $7.0 million for the first half of 2022. The decrease was primarily related to lower sales in the first half of 2023.

 

Gross profit was $4.2 million for the first half of 2023, or 53.4% of revenues, compared with $15.4 million, or 68.7% of revenues, for the first half of 2022. The decrease in gross profit was primarily driven by the lower number of units sold and higher costs charged by vendors in the first half of 2023.

 

Selling and marketing expense was $3.7 million for the first half of 2023, compared with $2.9 million for the first half of 2022. The increase was primarily attributable to an increase in tradeshow expense and headcount costs, partially offset by a decrease in commissions.

 

General and administrative expense was $2.7 million for the first half of 2023, compared with $2.4 million for the first half of 2022. The increase was primarily due to higher professional fees, offset by a reduction in insurance expense.

 

Research and development expense was $1.9 million for the first half of 2023, compared with $1.6 million for the first half of 2022. The increase was primarily due to expenses related to a project to develop a drug-delivery system for aesthetic use. The Company expects to complete this project by the end of 2023.

 

Other income of $0.5 million for the first half of 2023 was related to interest income. Other income of $12.8 million for the first half of 2022 was related to the gain on the sale of a non-core asset.

 

Net loss for the first half of 2023 was $2.3 million, or $0.14 per share, compared with net income of $19.6 million, or $1.17 per diluted share, for the first half of 2022. Net income for the 2022 period includes a $12.8 million gain on the sale of a non-core asset.

 

Adjusted EBITDA for the first half of 2023 was negative $3.7 million, compared with positive $21.5 million for the first half of 2022.

 

Use of Non-GAAP Financial Information

 

This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

 

3

 

 

SENSUS HEALTHCARE, INC.

GAAP TO NON-GAAP RECONCILIATION

(unaudited)

 

   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
(in thousands)  2023   2022   2023   2022 
                 
Net income, as reported  $(380)  $3,524   $(2,274)  $19,586 
Add:                    
Depreciation and amortization   84    74    155    166 
Stock compensation expense   67    40    209    97 
Income tax expense (benefit)   (502)   1,070    (1,303)   1,718 
Interest income, net   (245)   (24)   (488)   (27)
Adjusted EBITDA, non GAAP  $(976)  $4,684   $(3,701)  $21,540 

 

Conference Call and Webcast

 

Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss financial results for the 2023 second quarter, provide a business update and answer questions. To access the conference call, dial 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). The call will be webcast live and can be accessed at this link, or in the Investors section of the Company’s website at www.sensushealthcare.com.

 

Following the conclusion of the conference call, a replay will be available until September 3, 2023 and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 1356425. An archived webcast of the call will also be available in the Investors section of the Company’s website.

 

About Sensus Healthcare

 

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

 

For more information, visit www.sensushealthcare.com.

 

4

 

 

Forward-Looking Statements

 

This press release includes statements that are, or may be deemed, ’‘forward-looking statements.’’ In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

 

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

 

To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.

 

In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

 

Contact:

 

LHA Investor Relations

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com

 

(Tables to follow)

 

5

 

 

SENSUS HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

   For the Three Months Ended   For the Six Months Ended 
(in thousands, except share and per share data)  June 30,   June 30, 
   2023   2022   2023   2022 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
Revenues  $4,527   $12,080   $7,941   $22,417 
Cost of sales   1,908    3,824    3,700    7,013 
Gross profit   2,619    8,256    4,241    15,404 
Operating expenses:                    
Selling and marketing   1,595    1,728    3,693    2,946 
General and administrative   1,329    1,131    2,693    2,404 
Research and development   822    827    1,920    1,556 
Total operating expenses   3,746    3,686    8,306    6,906 
Income (loss) from operations   (1,127)   4,570    (4,065)   8,498 
Other income:                    
Gain on sale of assets   -    -    -    12,779 
Interest income   245    24    488    27 
Other income   245    24    488    12,806 
Net Income (loss) before income tax   (882)   4,594    (3,577)   21,304 
Provision for (benefit from) income tax   (502)   1,070    (1,303)   1,718 
Net Income (loss)  $(380)  $3,524   $(2,274)  $19,586 
Net income (loss) per share – basic  $(0.02)  $0.21   $(0.14)  $1.19 
– diluted  $(0.02)  $0.21   $(0.14)  $1.17 
Weighted average number of shares used in computing net income (loss) per share – basic   16,249,766    16,495,043    16,247,567    16,508,629 
– diluted   16,249,766    16,631,478    16,247,567    16,710,550 

 

6

 

 

SENSUS HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   As of
June 30,		   As of
December 31,		 
(in thousands, except shares and per share data)  2023   2022 
   (unaudited)     
Assets        
Current assets        
Cash and cash equivalents  $20,053   $25,520 
Accounts receivable, net   9,149    17,299 
Inventories   10,131    3,501 
Prepaid and other current assets   8,059    6,921 
Total current assets   47,392    53,241 
Property and equipment, net   367    243 
Intangibles, net   1    50 
Deposits   24    24 
Deferred tax asset   3,017    1,713 
Operating lease right-of-use assets, net   866    996 
Other noncurrent assets   350    468 
Total assets  $52,017   $56,735 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable and accrued expenses  $3,941   $5,521 
Product warranties   379    403 
Operating lease liabilities, current portion   181    190 
Income tax payable   -    890 
Deferred revenue, current portion   692    693 
Total current Liabilities   5,193    7,697 
Operating lease liabilities, net of current portion   698    830 
Deferred revenue, net of current portion   116    139 
Total liabilities   6,007    8,666 
Commitments and contingencies          
Stockholders’ equity          
Preferred stock, 5,000,000 shares authorized and none issued and outstanding   -    - 
Common stock, $0.01 par value – 50,000,000 authorized; 16,912,595 issued and 16,395,766 outstanding at June 30, 2023; 16,902,761 issued and 16,390,419 outstanding at December 31, 2022   169    169 
Additional paid-in capital   45,286    45,031 
Treasury stock, 516,829 and 512,342 shares at cost, at June 30, 2023 and December 31, 2022, respectively   (3,473)   (3,433)
Retained earnings   4,028    6,302 
Total stockholders’ equity   46,010    48,069 
Total liabilities and stockholders’ equity  $52,017   $56,735 

 

# # #

 

 

7

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 srts-20230803.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 srts-20230803_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 srts-20230803_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 03, 2023
Entity File Number 001-37714
Entity Registrant Name SENSUS HEALTHCARE, INC.
Entity Central Index Key 0001494891
Entity Tax Identification Number 27-1647271
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 851 Broken Sound Pkwy.
Entity Address, Address Line Two NW # 215
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33487
City Area Code 561
Local Phone Number 922-5808
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol SRTS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 ea182698-8k_sensus_htm.xml IDEA: XBRL DOCUMENT 0001494891 2023-08-03 2023-08-03 iso4217:USD shares iso4217:USD shares 0001494891 false 8-K 2023-08-03 SENSUS HEALTHCARE, INC. DE 001-37714 27-1647271 851 Broken Sound Pkwy. NW # 215 Boca Raton FL 33487 561 922-5808 false false false false Common Stock, par value $0.01 per share SRTS NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N M:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L5 M3,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I" M)\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF M"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( +V U&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U M4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL& MRF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " "]@ -799!YDAD! M #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8 MH*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0= M47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEX MZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1 M=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN# MOI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 M Q0 ( +V U<'04UB@0 +$ 0 " 0 !D;V-0 M&UL4$L! A0#% @ O8 #5P"-N!;O *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ O8 # M5YE&PO=V]R:W-H965T&UL4$L! A0#% @ O8 # M5Y^@&_"Q @ X@P T ( !L0P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ O8 #5R0> MFZ*M ^ $ !H ( !UA$ 'AL+U]R96QS+W=O9(9 0 SP, !, M ( !NQ( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ &!10 end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sensushealthcare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea182698-8k_sensus.htm ea182698ex99-1_sensus.htm srts-20230803.xsd srts-20230803_lab.xml srts-20230803_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea182698-8k_sensus.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea182698-8k_sensus.htm" ] }, "labelLink": { "local": [ "srts-20230803_lab.xml" ] }, "presentationLink": { "local": [ "srts-20230803_pre.xml" ] }, "schema": { "local": [ "srts-20230803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "SRTS", "nsuri": "http://sensushealthcare.com/20230803", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ea182698-8k_sensus.htm", "contextRef": "AsOf2023-08-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://sensushealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ea182698-8k_sensus.htm", "contextRef": "AsOf2023-08-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://sensushealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001213900-23-062982-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-062982-xbrl.zip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end